Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.54 |
| ▸ | DPP4 | P27487 | 3/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226561 | 0.92 | NOTUM (0.56) | CHRM4GPR119PANK3DPP4DPP8 | |
| SCHEMBL12639817 | 0.88 | GPR119 (0.56) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL3859652 | 0.88 | CHRM4 (0.54) | CHRM4GPR119PANK3DPP4DPP8 | |
| SCHEMBL16718831 | 0.83 | JAK2 (0.54) | CHRM4GPR119PANK3DPP4DPP8 | |
| SCHEMBL13622620 | 0.83 | KCNH2 (0.55) | CHRM4GPR119PANK3DPP4DPP8 | |
| SCHEMBL12099334 | 0.82 | GPR119 (0.55) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL3857665 | 0.81 | USP30 (0.60) | CHRM4GPR119PANK3DPP4LMNA | |
| SCHEMBL17687593 | 0.81 | GPR119 (0.52) | CHRM4GPR119PANK3DPP4DPP8 | |
| SCHEMBL26292225 | 0.80 | PANK3 (0.59) | CHRM4GPR119PANK3 | |
| SCHEMBL31289277 | 0.80 | GPR119 (0.56) | CHRM4GPR119PANK3DPP4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174635-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2024-05-30 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| EP-3917920-A1 | TLR INHIBITORS | Insilico Medicine IP Limited (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-113710659-A | TLR inhibitors | 英矽智能科技知识产权有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210253553-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| US-20210253553-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| US-11008303-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2021-05-18 | — | — | US | disclosed |
| US-11008303-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2021-05-18 | — | — | US | disclosed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
| EP-0592949-A2 | N-(aminocarbonyl)-piperidines/pepirazines as aggregation inhibiting agents | Dr. Karl Thomae GmbH (DE) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008303-B2 | TLR 9 inhibitors | TLR9, TLR1, TLR7 | CHRM4 2921/4885GPR119 32/4885PANK3 891/4885 |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | CHRM4 1153/4885GPR119 1784/4885PANK3 1553/4885 |
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | CHRM4 81/4885GPR119 235/4885PANK3 3384/4885 |
| US-20210253553-A1 | TLR 9 INHIBITORS | TLR9, TLR1, TLR7 | CHRM4 3124/4885GPR119 32/4885PANK3 770/4885 |
| US-11807622-B2 | TLR 9 inhibitors | TLR9, TLR1, TLR7 | CHRM4 3124/4885GPR119 32/4885PANK3 770/4885 |
| US-20240174635-A1 | TLR 9 INHIBITORS | TLR9, TLR1, TLR7 | CHRM4 3124/4885GPR119 32/4885PANK3 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.